{"entity":{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","aka":[],"tldr":"A second taxane that works after docetaxel and beat a second hormone pill head-to-head (CARD).","summary":"Cabazitaxel is a taxane with low affinity for the P-glycoprotein efflux pump, so it remains active in docetaxel-resistant disease. It is used in metastatic castration-resistant prostate cancer after docetaxel, with neutropenia as its main toxicity. TROPIC (2010) showed an overall survival benefit after docetaxel, and CARD (2019) showed it was superior to switching to a second androgen receptor pathway inhibitor in men who had already had one ARPI and docetaxel. It served as the comparator in TheraP, where it lost to 177Lu-PSMA-617 on PSA50 response (66% versus 37%) although overall survival was similar (HR 0.97), and in XALute against the T-cell engager xaluritamig. Its place relative to radioligands and T-cell engagers is therefore still being worked out. For a newcomer, it is the second taxane that works after docetaxel and beat a second hormone pill head-to-head.","status":"approved","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/Cabazitaxel","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabazitaxel"},{"label":"NICE TA391: cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel","url":"https://www.nice.org.uk/guidance/ta391"},{"label":"PROSELICA (Journal of Clinical Oncology 2017)","url":"https://doi.org/10.1200/JCO.2016.72.1076"}],"tags":[],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":["efflux-pump","prostate-crpc-sequencing","prostate-uk-drug-approvals"],"trials":["therap","xalute","nct07213674","nct07611110","nct06353386"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["NICE TA391 recommends cabazitaxel with prednisone or prednisolone for metastatic hormone-relapsed prostate cancer that has progressed during or after docetaxel, only if the person has an ECOG performance status of 0 or 1, has had at least 225 mg/m2 of docetaxel, and stops treatment at progression or after a maximum of 10 cycles, with the commercial arrangement in place. PROSELICA showed that 20 mg/m2 is non-inferior to 25 mg/m2 for overall survival (13.4 against 14.5 months) with grade 3 or 4 adverse events in 39.7 against 54.5 percent, which is the basis for starting an older or frailer man on the lower dose."],"brand":"Jevtana","modality":"Cytotoxic chemotherapy (taxane)","mechanism":"Taxane with low P-glycoprotein affinity, active in docetaxel-resistant disease.","approvals":[{"region":"US","year":2010,"indication":"mCRPC after docetaxel"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cabazitaxel/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"nail-changes-after-chemotherapy","kind":"technology","name":"Nails after chemotherapy: lifting, ridges and discolouration","route":"/technologies/nail-changes-after-chemotherapy/"},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}],"term":[{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/"},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/"},{"id":"prostate-crpc-sequencing","kind":"term","name":"What follows what in castration-resistant prostate cancer","route":"/terms/prostate-crpc-sequencing/"}],"trial":[{"id":"nct07213674","kind":"trial","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","route":"/trials/nct07213674/"},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/"},{"id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/"},{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/"},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/"},{"id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/"},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/"},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/"},{"id":"xalute","kind":"trial","name":"XALute","route":"/trials/xalute/"}],"paper":[{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/"}],"idea":[{"id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","kind":"idea","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/"}],"pathway":[{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"}]}}